307 related articles for article (PubMed ID: 25740413)
21. Molecular modeling of the alpha9alpha10 nicotinic acetylcholine receptor subtype.
Pérez EG; Cassels BK; Zapata-Torres G
Bioorg Med Chem Lett; 2009 Jan; 19(1):251-4. PubMed ID: 19013796
[TBL] [Abstract][Full Text] [Related]
22. The α9α10 nicotinic acetylcholine receptors antagonist α-conotoxin RgIA reverses colitis signs in murine dextran sodium sulfate model.
AlSharari SD; Toma W; Mahmood HM; Michael McIntosh J; Imad Damaj M
Eur J Pharmacol; 2020 Sep; 883():173320. PubMed ID: 32645334
[TBL] [Abstract][Full Text] [Related]
23. α-Conotoxin Vc1.1 Structure-Activity Relationship at the Human α9α10 Nicotinic Acetylcholine Receptor Investigated by Minimal Side Chain Replacement.
Chu X; Tae HS; Xu Q; Jiang T; Adams DJ; Yu R
ACS Chem Neurosci; 2019 Oct; 10(10):4328-4336. PubMed ID: 31411453
[TBL] [Abstract][Full Text] [Related]
24. Interaction of α9α10 Nicotinic Receptors With Peptides and Proteins From Animal Venoms.
Tsetlin V; Haufe Y; Safronova V; Serov D; Shadamarshan P; Son L; Shelukhina I; Kudryavtsev D; Kryukova E; Kasheverov I; Nicke A; Utkin Y
Front Cell Neurosci; 2021; 15():765541. PubMed ID: 35002625
[TBL] [Abstract][Full Text] [Related]
25. Conotoxin Interactions with α9α10-nAChRs: Is the α9α10-Nicotinic Acetylcholine Receptor an Important Therapeutic Target for Pain Management?
Mohammadi SA; Christie MJ
Toxins (Basel); 2015 Sep; 7(10):3916-32. PubMed ID: 26426047
[TBL] [Abstract][Full Text] [Related]
26. Effects of cyclization on stability, structure, and activity of α-conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABA(B) receptor.
Halai R; Callaghan B; Daly NL; Clark RJ; Adams DJ; Craik DJ
J Med Chem; 2011 Oct; 54(19):6984-92. PubMed ID: 21888386
[TBL] [Abstract][Full Text] [Related]
27. αO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human α9α10 subtype.
Zhangsun D; Zhu X; Kaas Q; Wu Y; Craik DJ; McIntosh JM; Luo S
Neuropharmacology; 2017 Dec; 127():243-252. PubMed ID: 28416445
[TBL] [Abstract][Full Text] [Related]
28. Are alpha9alpha10 nicotinic acetylcholine receptors a pain target for alpha-conotoxins?
Nevin ST; Clark RJ; Klimis H; Christie MJ; Craik DJ; Adams DJ
Mol Pharmacol; 2007 Dec; 72(6):1406-10. PubMed ID: 17804600
[TBL] [Abstract][Full Text] [Related]
29. Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor.
Li X; Tae HS; Chu Y; Jiang T; Adams DJ; Yu R
Pharmacol Ther; 2021 Jun; 222():107792. PubMed ID: 33309557
[TBL] [Abstract][Full Text] [Related]
30. Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist.
Luo S; Zhangsun D; Harvey PJ; Kaas Q; Wu Y; Zhu X; Hu Y; Li X; Tsetlin VI; Christensen S; Romero HK; McIntyre M; Dowell C; Baxter JC; Elmslie KS; Craik DJ; McIntosh JM
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4026-35. PubMed ID: 26170295
[TBL] [Abstract][Full Text] [Related]
31. Identification of a Novel O-Conotoxin Reveals an Unusual and Potent Inhibitor of the Human α9α10 Nicotinic Acetylcholine Receptor.
Jiang S; Tae HS; Xu S; Shao X; Adams DJ; Wang C
Mar Drugs; 2017 Jun; 15(6):. PubMed ID: 28598389
[TBL] [Abstract][Full Text] [Related]
32. Differential involvement of α4β2, α7 and α9α10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro.
Koval L; Lykhmus O; Zhmak M; Khruschov A; Tsetlin V; Magrini E; Viola A; Chernyavsky A; Qian J; Grando S; Komisarenko S; Skok M
Int J Biochem Cell Biol; 2011 Apr; 43(4):516-24. PubMed ID: 21146628
[TBL] [Abstract][Full Text] [Related]
33. Corrigendum: Crystal structure of the monomeric extracellular domain of α9 nicotinic receptor subunit in complex with α-conotoxin RgIA: Molecular dynamics insights into RgIA binding to α9α10 nicotinic receptors.
Zouridakis M; Papakyriakou A; Ivanov IA; Kasheverov IE; Tsetlin V; Tzartos S; Giastas P
Front Pharmacol; 2022; 13():980202. PubMed ID: 36091796
[TBL] [Abstract][Full Text] [Related]
34. α-Conotoxin RgIA and oligoarginine R8 in the mice model alleviate long-term oxaliplatin induced neuropathy.
Dyachenko IA; Palikova YA; Palikov VA; Korolkova YV; Kazakov VA; Egorova NS; Garifulina AI; Utkin YN; Tsetlin VI; Kryukova EV
Biochimie; 2022 Mar; 194():127-136. PubMed ID: 34979156
[TBL] [Abstract][Full Text] [Related]
35. alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells.
Elgoyhen AB; Vetter DE; Katz E; Rothlin CV; Heinemann SF; Boulter J
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3501-6. PubMed ID: 11248107
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological properties of alpha 9 alpha 10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras.
Baker ER; Zwart R; Sher E; Millar NS
Mol Pharmacol; 2004 Feb; 65(2):453-60. PubMed ID: 14742688
[TBL] [Abstract][Full Text] [Related]
37. Determination of the α-conotoxin Vc1.1 binding site on the α9α10 nicotinic acetylcholine receptor.
Yu R; Kompella SN; Adams DJ; Craik DJ; Kaas Q
J Med Chem; 2013 May; 56(9):3557-67. PubMed ID: 23566299
[TBL] [Abstract][Full Text] [Related]
38. Substitution of D-Arginine at Position 11 of α-RgIA Potently Inhibits α7 Nicotinic Acetylcholine Receptor.
Wu Y; Zhang J; Ren J; Zhu X; Li R; Zhangsun D; Luo S
Mar Drugs; 2023 May; 21(6):. PubMed ID: 37367650
[TBL] [Abstract][Full Text] [Related]
39. Structure and activity of alpha-conotoxin PeIA at nicotinic acetylcholine receptor subtypes and GABA(B) receptor-coupled N-type calcium channels.
Daly NL; Callaghan B; Clark RJ; Nevin ST; Adams DJ; Craik DJ
J Biol Chem; 2011 Mar; 286(12):10233-7. PubMed ID: 21252227
[TBL] [Abstract][Full Text] [Related]
40. Alpha9 alpha10 nicotinic acetylcholine receptors as target for the treatment of chronic pain.
Del Bufalo A; Cesario A; Salinaro G; Fini M; Russo P
Curr Pharm Des; 2014; 20(38):6042-7. PubMed ID: 24641230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
